stars 1 stars 2 stars 3

View CellFlow's top competitors like Biocartis, CureMetrix, and Cytora.

Tempus Labs, Inc.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Chicago, Illinois, US
Private
$210.1M Revenue
http://www.tempus.com
3.2K Employees
GRAIL
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Sunnyvale, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24
Menlo Park, California, US
Private
$109.7M Revenue
http://www.grail.com
1.1K Employees
Freenome
Freenome is a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests that can identify cancer in its earliest, most treatable stages. We operate an expansive, CLIA-certified clinical and research lab in our headquarters in Brisbane, CA. Our development of SimpleScreen CRC (approved by the FDA in July 2026) for colorectal cancer screening, SimpleScreen Lung (launched as a laboratory-developed test in October 2026) and a pipeline of tests for additional indications is designed to increase cancer screening participation among millions of at-risk individuals. Freenome went public in July 2026, entering Nasdaq under the ticker symbol “FRNM” and raising gross proceeds of $310 million. The company has a licensing agreement with Abbott to lead the U.S. commercialization of SimpleScreen CRC, as well as a strategic collaboration partnership with Roche for R&D and ex-U.S. commercialization of our screening technology. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross-functional collaboration, and whose work makes a significant impact on the company and their career.
Brisbane, California, US
Private
$132.1M Revenue
https://www.freenome.com/
406 Employees

Top CellFlow Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users